Late last week, Eli Lilly and Company (LLY - Free Report) provided its financial guidance for 2013 and commented on its 2012 guidance as well.
Regarding 2012 guidance, the company said that the impact of certain provisions of the American Taxpayer Relief Act of 2012 will be recognized in 2013 instead of 2012 as the enactment of the Act was completed earlier this year. These include the impact of the extension of the R&D tax credit for 2012. Eli Lilly said that the financial impact of the Act will be provided in details at its upcoming fourth quarter call on Jan 29.
The company continues to expect 2012 earnings in the range of $3.30 - $3.40 per share. The Zacks Consensus Estimate for 2012 is currently $3.36 per share, well within the company’s guidance range.
Moving on to 2013, Eli Lilly expects to earn $3.75 - $3.90 per share on total revenues of $22.6 billion - $23.4 billion. Eli Lilly, which is currently going through a patent cliff with the loss of exclusivity on Zyprexa, will be losing US exclusivity on Cymbalta in Dec. While revenues will be impacted by the loss of Cymbalta exclusivity and the loss of the 15% royalty on exenatide sales, products like Humalog, Humulin, Cialis, Strattera, Forteo, Alimta, Cymbalta (outside the US), Effient, Tradjenta and Axiron, and the animal health segment should contribute to sales. Japan and emerging markets, especially China, should also drive sales.
Eli Lilly will continue working on containing costs and expects total operating expenses to remain flat or decline slightly from 2012 levels. While the company expects marketing, selling and administrative expenses to remain flat or decline from 2012 levels to $7.1 - $7.4 billion, R&D expenses are expected to remain flat or increase or 2012 levels to $5.2 - $5.5 billion. Eli Lilly currently has 13 candidates in late-stage development.
Meanwhile, the company maintained its mid-term guidance. From now through 2014, the company expects annual net income of at least $3 billion on revenues of at least $20 billion. Operating cash flow is expected to be at least $4 billion every year during this time period.
Eli Lilly said that it expects operating cash flows to be enough to fund capital expenditures of approximately $900 million, dividends (of about $2.1 billion), the new $1.5 billion share buyback program as well as anticipated business development activity. The company has already purchased shares worth $400 million and expects to complete the balance $1.1 billion buyback in 2013.
Although Eli Lilly’s 2013 revenue guidance was in-line with expectations (the Zacks Consensus Estimate currently stands at $23.3 billion), earnings guidance was above expectations (the Zacks Consensus Estimate is currently $3.73 per share). Share buybacks and cost control should help the company achieve its 2013 guidance despite the presence of generic competition for key products.
We currently have a Neutral recommendation on Eli Lilly, which carries a Zacks #3 Rank (Hold). Large-cap pharma companies that currently look better-positioned include Novo Nordisk (NVO - Free Report) , Sanofi (SNY - Free Report) and Novartis (NVS - Free Report) . All three companies carry a Zacks #2 Rank (Buy).